She is CSL Behring's new Nordic General Manager
Av – It feels very exciting. CSL is an interesting company, though unknown to many, that does a lot of good for many patients, says Helena Bragd to Life Science Sweden.
Helena Bragd most recently worked at the medtech company Becton Dickinson where she was the Nordic General Manager for eight years. Before that, she held strategic positions at Eli Lilly, Johnson & Johnson, and ResMed. She also served as the chairperson of Swedish Medtech from 2019 to 2023.
The development is moving at lightning speed
– I have worked in life science and medtech for 25 years. It is a rewarding industry to be in. I enjoy working with products and therapies that can truly help Nordic healthcare advance to the next level. We have come quite far in some areas, but there is so much more to do, and the development is moving at lightning speed.
CSL Behring is a global biotech company specializing in drug development within immunology and hematology, among other fields. The company particularly focuses on rare diseases.
– CSL is developing several new and innovative products, including a gene therapy for hemophilia that has now been launched in Denmark. But everything is still very new to me, and I am still learning more about these advanced products.
The goal moving forward is to get more products approved in the Nordics so that more patients can benefit from the new treatments available, continues Helena Bragd.
– I have experience working with patients who suffer from rare diseases, and I know what a new drug, a new therapy, can do to improve their quality of life, she says.
Artikeln är en del av vårt tema om News in English.